obstructive sleep apnea Archives | Be Korea-savvy
Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Mont-Saint-Guibert (Belgium), Sept. 14 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S. Food and Drug Administration (FDA) has granted the Genio® bilateral hypoglossal nerve stimulation system Breakthrough Device Designation for the treatment [...]

Nyxoah Receives FDA Approval for Full-body 1.5T and 3T MRI Compatibility for the Genio® System to Treat Obstructive Sleep Apnea (OSA)

Nyxoah Receives FDA Approval for Full-body 1.5T and 3T MRI Compatibility for the Genio® System to Treat Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium, Feb. 9 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces that the Company has received approval by the Food and Drug Administration (FDA) for the Magnetic Resonance Imaging (MRI) conditional [...]

Nyxoah and Vanderbilt University Enter Exclusive Licensing Agreement Regarding Next Generation Neurostimulation Technologies to Treat Obstructive Sleep Apnea (OSA)

Nyxoah and Vanderbilt University Enter Exclusive Licensing Agreement Regarding Next Generation Neurostimulation Technologies to Treat Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium, Feb. 2 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive license agreement with Vandebilt University, Nashville – TN, USA. The agreement allows Nyxoah to [...]

Nyxoah Announces Full-body 1.5T and 3T MRI Compatibility for the Genio® System to Treat Obstructive Sleep Apnea (OSA)

Nyxoah Announces Full-body 1.5T and 3T MRI Compatibility for the Genio® System to Treat Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium, Jan. 26 (Korea Bizwire) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE Mark Magnetic Resonance Imaging (MRI) conditional labeling for the current Genio® neurostimulation-based OSA therapy to [...]

First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)

First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium, Jan. 5 (Korea Bizwire) – Nyxoah S.A. (EBR: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the successful implantation of the first US patient in the DREAM pivotal IDE study. The implantation took place at the [...]

Nyxoah Receives IDE Approval from the U.S. Food and Drug Administration (FDA) for its DREAM Study

Nyxoah Receives IDE Approval from the U.S. Food and Drug Administration (FDA) for its DREAM Study

Mont-Saint-Guibert, Belgium, June 25 (Korea Bizwire) - Nyxoah S.A., a healthtech company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to allow Nyxoah to commence its pivotal DREAM [...]

Philips Launches NightBalance, Increasing Therapy Options for Positional Obstructive Sleep Apnea Patients

Philips Launches NightBalance, Increasing Therapy Options for Positional Obstructive Sleep Apnea Patients

Amsterdam, the Netherlands, Sept. 17 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the commercial launch of Philips NightBalance, a prescription sleep position therapy device designed for patients with positional obstructive sleep apnea (OSA). A mask-free alternative to existing positional OSA treatments, Philips NightBalance is a [...]